Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 60

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---
 cost of revenue of $2.9 million and gross losses of $1.4 million for the six months ended September 30, 2024.

Revenues
continue to expand as we continue to sign hospital contracts and begin selling into international markets. The reduction in gross losses
is primarily associated with sales growth, partially offset by one-time costs required to upgrade our existing fleet of devices and provisions
for excess inventory.

Research
and Development Expenses

Research
and development expenses for the three months ended September 30, 2025 were $2.5 million as compared to $4.6 million for the three months
ended September 30, 2024. The decrease of $2.1 million was primarily attributed to a decrease in spend in salaries $0.6 million ($0.3
million in Beyond Air and $0.3 million in Beyond Cancer), stock-based compensation costs $0.1 million (less than $0.1 million in Beyond
Air and less than $0.1 million in Beyond Cancer), pre-clinical expenses $0.2 million ($0.1 million in Beyond Cancer and $0.1 million
in NeuroNos), professional fees $0.2 million ($0.1 million in Beyond Air and $0.1 million in Beyond Cancer), and a reduction in Gen II
device development costs of $1.0 million.

Research
and development expenses for the six months ended September 30, 2025 were $5.5 million as compared to $10.6 million for the six months
ended September 30, 2024. The decrease of $5.1 million was attributed primarily to a decrease in spend in salaries $1.9 million ($0.8
million in Beyond Air and $1.1 million in Beyond Cancer), stock compensation costs $0.4 million ($0.2 million in Beyond Air and $0.2
million in Beyond Cancer), pre-clinical expenses $0.6 million ($0.3 million in Beyond Cancer and $0.3 million in NeuroNos), professional
fees $0.5 million ($0.3 million in Beyond Air and $0.2 million in Beyond Cancer), travel expenses $0.1 million, depreciation $0.1 million,
and a reduction in Gen II device development costs of $1.2 million.

Selling,
General and Administrative Expenses

Selling,
general and administrative expenses for the three months ended September 30, 2025 were $4